Tongxinluo-pretreated mesenchymal stem cells facilitate cardiac repair via exosomal transfer of miR-146a-5p targeting IRAK1/NF-κB p65 pathway

Yuyan Xiong, Ruijie Tang, Junyan Xu, Wenyang Jiang, Zhaoting Gong, Lili Zhang, Yu Ning, Peisen Huang, Jun Xu, Guihao Chen, Xiaosong Li, Mengjin Hu, Jing Xu, Chunxiao Wu, Chen Jin, Xiangdong Li, Haiyan Qian and Yuejin Yang*

Abstract

Background: Bone marrow cells (BMCs), especially mesenchymal stem cells (MSCs), have shown attractive application prospects in acute myocardial infarction (AMI). However, the weak efficacy becomes their main limitation in clinical translation. Based on the anti-inflammation and anti-apoptosis effects of a Chinese medicine-Tongxinluo (TXL), we aimed to explore the effects of TXL-pretreated MSCs (MSCsTXL) in enhancing cardiac repair and further investigated the underlying mechanism.

Methods: MSCsTXL or MSCs and the derived exosomes (MSCsTXL-exo or MSCs-exo) were collected and injected into the infarct zone of rat hearts. In vivo, the anti-apoptotic and anti-inflammation effects, and cardiac functional and histological recovery were evaluated. In vitro, the apoptosis was evaluated by western blotting and flow cytometry. miRNA sequencing was utilized to identify the significant differentially expressed miRNAs between MSCsTXL-exo and MSCs-exo, and the miRNA mimics and inhibitors were applied to explore the specific mechanism.

Results: Compared to MSCs, MSCsTXL enhanced cardiac repair with reduced cardiomyocytes apoptosis and inflammation at the early stage of AMI and significantly improved left ventricular ejection fraction (LVEF) with reduced infarct size in an exosome-dependent way. Similarly, MSCsTXL-exo exerted superior therapeutic effects in anti-apoptosis and anti-inflammation, as well as improving LVEF and reducing infarct size compared to MSCs-exo. Further exosomal miRNA analysis demonstrated that miR-146a-5p was the candidate effector of the superior effects of MSCsTXL-exo. Besides, miR-146a-5p targeted and decreased IRAK1, which inhibited the nuclear translocation of NF-κB p65 thus protecting H9C2 cells from hypoxia injury.

Conclusions: This study suggested that MSCsTXL markedly facilitated cardiac repair via a new mechanism of the exosomal transfer of miR-146a-5p targeting IRAK1/NF-κB p65 pathway, which has great potential for clinical translation.

Keywords: Myocardial infarction, Mesenchymal stem cells, Exosomes, Tongxinluo, Pretreatment

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Ischemic heart disease has long been a major cause of cardiovascular disease mortality worldwide despite improved medical care and even reperfusion therapy for acute myocardial infarction (AMI) [1, 2]. Sudden loss
of massive cardiomyocytes accompanied by an intense inflammatory response in the early stage of AMI correlated directly with deteriorated cardiac function, ventricular remodeling, heart failure and worse clinical outcomes [3–5]. Bone marrow cell (BMC) transplantation, including mesenchymal stem cell (MSC) transplantation, remains a promising method for the treatment of patients with AMI and ischemic heart failure [6]. However, the weak therapeutic effects of transplanted BMCs and MSCs have restricted their clinical applications [7–11]. Although numerous studies have explored different strategies to enhance the effects of MSCs including preconditioning [12, 13], genetic modification [14, 15] and tissue engineering [16, 17], some of these strategies are still challenging with respect to clinical translation in current AMI treatment.

Our group has explored a clinically feasible strategy to enhance the therapeutic efficacy of MSCs by pretreatment with the widely used clinical medicine statins and the Chinese medicine compound Tongxinluo (TXL) in preclinical and clinical studies [18–21]. Both statins and TXL share similar anti-inflammatory and anti-apoptotic mechanisms, resulting in microenvironment improvement in the post-infarct myocardium and facilitating the survival of implanted MSCs [18–20]. Statins and TXL have also been confirmed to protect MSCs from hypoxia and serum deprivation (H/SD)-induced apoptosis in vitro [22, 23] and exerted anti-apoptotic effects in vivo [24, 25]. In addition, MSCs pretreated with statins demonstrated marked therapeutic potential [26–28], though the effects of TXL-pretreated MSCs (MSCsTXL) have not yet been explored. We herein aimed to explore whether MSCsTXL could enhance cardiac repair effects in AMI and the underlying mechanism.

The therapeutic effects of MSCs on cardiac repair have been attributed to their paracrine mechanism [29] including microvesicles and exosomes, which play pivotal roles in intercellular communication [30, 31]. Among these, MSCs-derived exosomes exhibit distinct benefits in improving harsh environments and promoting cardiac recovery after AMI [32]. Exosomes, 30–150 nm extracellular vesicles, manifest several favorable features including low immunogenicity and reduced biodegradability and are capable of carrying a complex cargo of bioactive molecules including proteins, lipids and RNAs to mediate intercellular communications [33, 34]. MicroRNAs (miRNAs) are a class of short noncoding RNAs regulating gene expression at the posttranslational level [35], and exosomal miRNAs have been found to play an important role in cardiac repair [36]. Therefore, we hypothesized that miRNAs in MSCsTXL-derived exosomes (MSCsTXL-exo) might be essential to the MSCsTXL-mediated cardioprotective effects in AMI.

In the present study, we first reported the superior efficacy of MSCsTXL relative to MSCs especially in anti-apoptosis and anti-inflammation at an early stage, as well as cardiac function recovery in an exosome-dependent manner. Further analysis found that exosomal miR-146a-5p levels were upregulated and then transferred to cardiomyocytes, which targeted the IRAK1/NF-κB p65 signaling pathway, thus ameliorating cardiomyocyte injury. These findings provide new insights into the novel mechanism of MSCsTXL in enhancing the effects of cardiac repair in AMI.

**Methods**

All animals were obtained from the Animal Department of Fuwai Hospital. The experiment was performed with approval of the Experimental Animals Ethics Committee of Fuwai Hospital (FW-2018-0010), and all procedures conformed to National Institutes of Health guidelines. A more detailed description of the experimental procedures is available in the Additional file 1.

**MSCs isolation and pretreatment**

Sprague–Dawley (SD) rats were housed in a pathogen-free conditions under a controlled 12-h light–dark cycle and allowed free access to water and chow. Bone marrow was flushed with medium from the tibia and femur of male SD rats (60–80 g) and cultured in complete medium (IMDM, 10% fetal bovine serum) in 5% CO₂ at 37 °C. After 24 h, remove the nonadherent cells that accumulate on the surface of the dish by changing the medium and replacing with fresh IMDM with 10% FBS and penicillin (100 U/mL)/streptomycin (100 μg/mL). MSCs at passages 3–4 appeared spindle shaped and were identified by canonical surface marker probing as CD45−, CD29+, CD90+, CD73+. Passage 3–4 MSCs were pretreated with TXL solution for 24 h.

**Exosome extraction, identification and labeling**

Exosomes were isolated by differential centrifugation. Briefly, MSCs were cultured in exosome-free FBS containing IMDM for 48 h. The conditioned supernatants of MSCs pretreated with TXL or not were then collected and centrifuged. The conditioned supernatants were first centrifuged at 300 g for 10 min and 2000 g for 20 min to remove cells and debris and then centrifuged at 16500 g for 30 min to eliminated large extracellular vesicles. The crude exosome pellet was obtained by ultracentrifuging at 120000 g for 70 min, then the pellet was washed in Phosphate-buffered saline (PBS, pH7.4) followed by repeat ultracentrifugation for 70 min at the same speed. The exosome pellet was then suspended in appropriate volume of PBS and stored at −80 °C for the use in the experiments.
Protein concentrations of exosome were measured by microBCA protein assay kit (Thermo Fisher Scientific). Shape and sizes of exosomes were identified by transmission electron microscope (TEM, FEI, Tecnai G2 Spirit BioTwin) and Nanoparticle Tracking Analysis (NTA, PARTICLE METRIX, ZetaVIEW). Additionally, exosomes were identified by using western blotting with antibodies against CD63, TSG101, and Alix, whose catalog numbers are listed in Additional file 1: Table S1.

To determine whether exosomes can be effectively taken, purified exosomes were labeled with fluorescent dye PKH26 using Red Fluorescent Cell Linker Kit (Sigma-Aldrich) according to the manufacturer’s instructions and washed in PBS followed by two times of ultracentrifugation to remove the extra dye. After 12, or 24 h incubation with pre-labeled exosomes, H9C2 cells were then washed with PBS, fixed with 4% paraformaldehyde, then stained with phalloidine and DAPI at room temperature. For in vivo experiments, PKH26 pre-labeled exosomes were injected into the border zone of the infarcted heart and the distribution of pre-labeled exosomes were then monitored by confocal microscopy.

AMI model establishment
Animals were randomized into different groups. Female SD rats (200–220 g weight) were anesthetized by intraperitoneal injection of pentobarbital sodium (50 mg/kg) before the surgical procedure. A 6–0 polyester suture was used to ligate the left anterior descending coronary artery (LAD). Thirty minutes after ligation, MSCs (2 × 10^6 MSCs, in 100 μL PBS) or exosomes (20 μg, in 100 μL PBS) or 100 μL PBS was injected into the border zone of the infarcted heart at three sites. Transthoracic two-dimensional M-mode echocardiography was performed at 3 days (baseline) and 28 days (endpoint) post-AMI with VisualSonics Vevo 2100 system after rats were anesthetized with isoflurane. Rats were then placed on a heating pad, keeping the heart rate > 350 b.p.m. and the core body temperature ~ 37 °C. Left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), left ventricular end-diastolic volume (LVEDV), and left ventricular end-systolic volume (LVESV) were assessed and calculated as previously described [37].

Histological analysis
Rats were killed after echocardiography measurements were recorded. Masson’s trichrome and Sirius red staining were used to quantify the extent of the infarct size and fibrosis in the left ventricle (LV) with Image software. Infarct size was calculated as [(epicardial infarct ratio + endocardial infarct ratio)/2] × 100. The epicardial infarct ratio was obtained by dividing epicardial infarct length by the epicardial circumference. The endocardial infarct ratio was calculated similarly. Collagen area was quantified as the average ratio of collagen area to the total LV area (collagen area/total LV area × 100%). Hematoxylin–eosin (HE) staining was used to roughly evaluate the degree of inflammatory cell infiltration. Vascular density was quantified by immunofluorescence of α-SMA and CD31 as described in the Additional file 1. The number of apoptotic cardiomyocytes was counted by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, as described in the Additional file 1.

Apoptosis determination by flow cytometry
H9C2 cells, pretreated by exosomes for 24 h or transfected with miRNA mimics, inhibitors or siRNA, were exposed to H/SD condition. Then H9C2 cells were collected and measured by using the Annexin V-FITC/PI Kit (Becton, Dickinson and Company) according to the manufacturer’s protocol. Viable cells were defined as Annexin V−/PI−, early apoptotic cells as Annexin V+/PI−, late apoptotic and necrotic cells as annexin V+/PI+. The proportion of apoptotic cells was calculated after adding together early and late apoptotic cells.

miRNA mimics or inhibitors and siRNA transfection
miR-146a-5p mimics, inhibitors, interleukin 1 receptor-associated kinase 1 (Irak1) siRNA and their negative controls (NCs) were purchased from RiboBio. Target cells (MSCs or H9C2 cells) were transfected with miR-146a-5p mimics (100 nM), or miR-146a-5p inhibitors (200 nM), Irak1 siRNA (100 nM) or relative NC (100–200 nM) by using Lipofectamine RNAiMAX (Invitrogen) according to manufacturer’s instructions. After 6 h of incubation, the medium was replaced with fresh medium, and then the cells were cultured for 48 h.

Exosomal miRNA sequencing
The miRNA sequencing was performed both in MSCs-derived exosomes (MSCs-exo) and MSCsTXL-derived exosomes (MSCsTXL-exo). Three samples were processed for each group. Exosomal RNA was used to prepare miRNA next-generation sequencing (NGS) libraries with the QIAseq miRNA Library Kit. The libraries obtained from different samples were then performed on an Illumina Hiseq X Ten platform. Differentially expressed miRNAs were identified by |fold change| > 2 and p value < 0.05 with the threshold set for up- and downregulated genes.

Dual-luciferase reporting system
HEK293T cells were plated in a 96-well plate at 1 × 10^4 cells/well for 24 h, and transfection was performed once the cells achieved 60–70% confluency. Lipo6000™
(Beyotime Biotechnology) was used to transfect the cells. After 48 h transfection, miRNA level was detected by chemiluminescence using the Dual-Luciferase Reporter Assay System (Promega).

**Quantitative real-time-polymerase chain reaction (qRT-PCR)**

Total RNA and miRNA were extracted from exosomes, cells and tissues with Trizol reagent (Life Technologies) according to the manufacturer’s instructions. mRNAs reverse transcription was performed using a PrimeScript™RT Reagent Kit with gDNA Eraser (Takara) and miRNAs were reverese transcribed with a Bulge-Loop miRNA qRT-PCR Starter Kit (RiboBio). The quantita-

and miRNAs were revere transcribed with a Bulge-Loop

Biosystem). The level of mRNA and miRNA was nor-

on a QuantStudio 3 Real-Time PCR system (Applied

as confirmed by oil red O staining, alizarin red staining

and alcian blue staining, respectively (Additional file 1:

Fig. S1A). To assess the appropriate pretreatment concentra-

tions of TXL, different concentrations of TXL were

applied to MSCs. The cell viability of MSCs obvi-

ously decreased under normal conditions when the con-

centration was above 800 μg/mL, while a 100–400 μg/

mL concentration resulted in a dose-dependent increase

in cell viability under H/SD conditions, as shown by the

CCK-8 assay (Additional file 1: Fig. S1B). Thus, we chose

a concentration of 400 μg/mL for the pretreatment of

MSCs (MSCsTXL). Further analysis showed that MSCsTXL

had similar surface markers and differentiation ability as

MSCs (Additional file 1: Fig. S1C-D).

To investigate whether TXL pretreatment could

enhance the therapeutic efficiency of MSCs, MSCs pre-

treated with TXL (MSCsTXL group), MSCs (MSCs group),

or PBS (AMI group) was intramyocardially injected into

the border zone of infarcted rat hearts 30 min post-AMI.

Three days post injection, the MSCsTXL group revealed

fewer apoptotic cardiomyocytes (cTNT“TUNEL“) in

the ischemic border zone than those receiving PBS or

MSCs treatment (Fig. 1B, C). Western blot analysis also

indicated reduced apoptosis in the MSCsTXL group as

the pro-apoptotic Bax and cleaved-Caspase 3 level was

decreased significantly in the MSCsTXL group (Fig. 1D–

F; Additional file 1: Table S3). Furthermore, HE staining

roughly showed decreased infiltration of inflammatory

cells in the MSCsTXL group (Additional file 1: Fig. S2A),

and the ELISA results indicated the decreased levels

of inflammatory cytokines including IL-6 and TNF-α,

in the infarct border zone (Fig. 1G, H, Additional file 1:

Table S3).

Four weeks post-AMI, both MSCs and MSCsTXL

administration exhibited significant improvement in

LVEF compared to the AMI group, while MSCsTXL dem-

onstrated a therapeutic superiority to MSCs in systolic

function improvement (49.69 ± 6.02% vs. 42.10 ± 3.83%,

p < 0.05) (Fig. 2A, B, Additional file 1: Table S3), with

a significantly smaller infarct size in the MSCsTXL

group compared to the MSCs (46.39 ± 8.06% vs.

5.41% ± 5.41%, p < 0.05) and AMI groups (46.39 ± 8.06%

vs. 66.29 ± 4.96%, p < 0.0001) by Masson’s trichrome

staining analysis (Fig. 2C, D, Additional file 1: Table S3).
Fig. 1 (See legend on previous page.)
In addition, the collagen area determined by Sirius red staining decreased significantly in both the MSCsTXL and MSCs group ($p<0.01–0.001$), while there was no obvious difference between them (Fig. 2E, F). Arteriole density (determined by α-SMA immunofluorescence staining) and capillary density (determined by CD31 immunofluorescence staining) in the ischemic border zone were both significantly increased in the MSCsTXL and MSCs group ($p<0.05–0.0001$) (Fig. 2G–J, Additional file 1: Table S3).

Taken together, these data indicated that TXL pre-treatment enhanced the therapeutic efficacy of MSCs in cardiac repair, especially in protecting cardiomyocytes against apoptosis and limiting inflammation at an early stage of AMI.

GW4869 abolished the superior effects of MSCsTXL

As a blocker of neutral sphingomyelinase that inhibits exosome secretion, GW4869 could inhibit exosome production in a dose-dependent manner with complete blockage at a concentration of 20 μM which do not affect cell viability [38–40]. After pretreatment of MSCsTXL with 20 μM GW4869 for 24 h, we found that GW4869 pretreatment effectively blocked the release of exosomes (Additional file 1: Fig. S2B) and abrogated the effects of MSCsTXL in reducing apoptosis, limiting inflammation (Fig. 1B–H, Additional file 1: Table S3), improving cardiac function, decreasing infarct and fibrotic size, and promoting angiogenesis (Fig. 2A–J, Additional file 1: Table S3). Therefore, these results indicated that exosomes derived from MSCsTXL are vital for cardiac repair.

MSCsTXL-exo exhibited better effects in inhibiting cardiomyocyte apoptosis in vitro

Since the cardioprotective roles of MSCs against MI injury were mainly mediated by exosomes [39, 41, 42] and those of MSCsTXL were also abolished by GW4869 pretreatment, we further investigated whether MSCsTXL facilitate cardiac repair via exosomes. Exosomes, isolated by ultracentrifugation, were characterized by TEM (Fig. 3A) as having similar particle sizes and concentrations between MSCs-derived exosomes (MSCs-exo) and MSCsTXL-exo (Fig. 3B). The exosomes were positive for exosome-specific markers including Alix, Tsg101 and CD63, as well as the MSCs surface marker CD73 (Fig. 3C). H9C2 cells were cocultured with PKH26-labeled exosomes for 12 and 24 h, and exosomal uptake was further verified via PKH26 fluorescence images. As shown in Fig. 3D, the uptake rate was positively correlated with the cocultivation time. Three days after PKH26-labeled exosome injection, confocal images indicated that these injected exosomes could be taken up by cardiomyocytes in vivo (Fig. 3E).

In vitro, to evaluate the protective effects of exosomes, H9C2 cells were pretreated with different concentrations of MSCs-exo for 24 h and then subjected to H/SD. Treatment with exosomes at a concentration of 10–20 μg/mL resulted in a dose-dependent decrease in apoptosis compared to H/SD group, with no significant difference among the 10, 15 and 20 μg/mL groups (Fig. 4A, B). Thus, we chose a concentration of 10 μg/mL for the following in vitro assays. When the same concentration (10 μg/mL) of MSCs-exo and MSCsTXL-exo was applied to H9C2 cells, the apoptotic ratio significantly dropped in both the MSCs-exo and MSCsTXL-exo treated group compared to the H/SD group (33.34 ± 6.07% and 25.22 ± 3.35% vs. 43.78 ± 4.70%, $p<0.01$ and $p<0.001$, respectively), with a significantly more decrease in the latter group than the former one ($p<0.05$) (Fig. 4C, D, Additional file 1: Table S4). Further western blot analysis validated that MSCsTXL-exo were superior to MSCs-exo in decreasing the level of cleaved-Caspase 3 (Fig. 4E–G, Additional file 1: Table S4). These results demonstrated the superior protective effects of MSCsTXL-exo compared to MSCs-exo in protecting H9C2 cells against hypoxia-induced apoptosis.

MSCsTXL-exo demonstrated better functional recovery by reducing apoptosis and suppressing inflammation

We further compared the therapeutic efficacy between MSCsTXL-exo and MSCs-exo in vivo. Consistent with previous results of animals receiving MSCs and MSCsTXL, the MSCsTXL-exo group exhibited significantly fewer apoptotic cardiomyocytes (cTNT+/TUNEL+), lower levels of pro-apoptotic Bax and cleaved-Caspase 3 and inflammatory cytokines, as well as a higher LVEF and smaller infarct size (Fig. 5A–K, Additional file 1: Table S5) when compared to the MSCs-exo group. The MSCsTXL-exo group also showed a trend of collagen area reduction.
Fig. 2 (See legend on previous page.)
Fig. 3 Characterization of exosomes derived from MSCs. A MSCs-exo and MSCs\textsuperscript{TXL}-exo were assessed by TEM and exhibited cup-shaped morphology. Scale bar = 200 μm. B NTA was performed to characterize the particle size and concentration. C Representative western blotting images of exosomal protein markers and MSCs markers. D Representative confocal images indicated that PKH26 labeled exosomes were taken up by H9C2 cells after 12 or 24 h of incubation. Scale bar = 20 μm. E PKH26-labeled MSCs-exo could be taken up by cardiomyocytes in infarcted hearts on Day 3 post-AMI. Scale bar = 50 μm.
and angiogenesis promotion over the MSCs-exo group, although the difference was not significant (Fig. 5L–Q, Additional file 1: Table S5). These results indicated that MSCsTXL-exo had superior cardioprotective effects than MSCs-exo in vivo, especially in reducing apoptosis and suppressing inflammation.
**miR-146a-5p was the candidate effector of MSCs<sub>TXL</sub>-exo in mediating cardioprotective effects**

Since exosomal miRNAs are vital in intercellular communication, we sought to investigate the miRNA expression profiles between MSCs<sub>TXL</sub>-exo and MSCs-exo to further elucidate the mechanism. miRNA sequencing analysis demonstrated 43 differentially expressed miRNAs, with a twofold change and \( p < 0.05 \) threshold cutoff (Fig. 6A, B). Among the differentially expressed miRNAs, 18 miRNAs were upregulated in MSCs<sub>TXL</sub>-exo. Based on the superior effects of MSCs<sub>TXL</sub>-exo in inflammation modulation and cardiac repair, we searched for widely reported miRNAs involved in either inflammation modulation (miR-214, miR-126, miR-221, miR-210, miR-132, miR-146a, miR-24 and miR-21) or cardiac repair (miR-27a, miR-125, miR-155, miR-124, miR-223, miR-146a, miR-21 and miR-24). miR-146a stood out as a candidate effector, which is enriched in MSCs<sub>TXL</sub>-exo and probably responsible for reducing apoptosis and suppressing inflammation after AMI, as shown in Fig. 6C.

To validate the miRNA-profile results, we tested the levels of miR-146a-5p in MSCs-exo and MSCs<sub>TXL</sub>-exo. Compared to MSCs-exo, TXL pretreatment significantly upregulated the level of miR-146a-5p in MSCs<sub>TXL</sub>-exo (> tenfold, \( p < 0.001 \)) (Fig. 6D). In addition, TXL pretreatment also increased miR-146a-5p levels in MSCs<sub>TXL</sub> compared to MSCs (\( p < 0.01 \)) (Fig. 6E).

To explore the relationship between miR-146a-5p and the cardioprotective effects of TXL pretreatment, we measured the miR-146a-5p levels in the infarct border zone of rat hearts 4 weeks post-AMI. qPCR analysis confirmed the significantly higher level of miR-146a-5p in the MSCs<sub>TXL</sub>-exo group than in the MSCs-exo and PBS group (\( p < 0.05 \)–0.001) (Fig. 6F). Similarly, in an in vitro experiment, after coculture with MSCs-exo or MSCs<sub>TXL</sub>-exo for 24 h, H9C2 cells exhibited significantly increased levels of miR-146a-5p (\( p < 0.05 \)–0.001) with a much higher level in MSCs<sub>TXL</sub>-exo than in MSCs-exo (\( p < 0.0001 \)) (Fig. 6G). To validate the vital role of miR-146a-5p in the cardioprotective effects of MSCs<sub>TXL</sub>-exo, miR-146a-5p loss-of-function studies were performed in MSCs<sub>TXL</sub>. MSCs<sub>TXL</sub> were transfected with miR-146a-5p inhibitors (MSCs<sub>TXL</sub>-inhibitors) or its negative control (MSCs<sub>TXL</sub>-inhibitors-NC), and exosomes were then isolated from the conditioned medium. The efficiency of miR-146a-5p knockdown in both MSCs<sub>TXL</sub> and its derived exosomes was quantified (Fig. 6H-I). Flow cytometry analysis showed that miR-146a-5p inhibition significantly increased MSCs<sub>TXL</sub>-exo-mediated apoptosis than inhibitors-NC (34.44 ± 5.25% vs. 26.54 ± 4.80%, \( p < 0.05 \)) (Fig. 6J, K, Additional file 1: Table S7). Western blot analysis also showed significantly increased expression of both pro-apoptotic Bax and cleaved-caspase 3 in H9C2 cells treated with MSCs<sub>TXL</sub>-inhibitors-exo compared to MSCs<sub>TXL</sub>-inhibitors-NC-exo (both \( p < 0.05 \)) (Fig. 6L–N, Additional file 1: Table S7), indicating the vital role of miR-146a-5p in mediating the cardioprotective effects of TXL pretreatment.

Therefore, the above results demonstrated that TXL pretreatment enhanced the therapeutic efficacy of MSCs by upregulating exosomal miR-146a-5p levels.

**miR-146a-5p protected H9C2 cells from apoptosis by targeting IRAK1 and inhibiting the nuclear translocation of the NF-κB p65 subunit**

The level of miR-146a-5p was examined in H9C2 cells after H/SD. The results showed that miR-146a-5p was significantly decreased under hypoxic injury (Fig. 7A), suggesting a possible connection between the reduction in miR-146a-5p and apoptosis of H9C2 cells under H/SD conditions. To further validate the protective role of miR-146a-5p, we directly tested the effects of miR-146a-5p mimics, inhibitors or respective NCs in H9C2 cells under H/SD conditions. miR-146a-5p mimics or inhibitors were confirmed to significantly increase or decrease miR-146a-5p levels in H9C2 cells, respectively (both \( p < 0.001 \)) (Fig. 7B, C). Under H/SD condition, flow cytometry analysis demonstrated that miR-146a-5p mimics significantly reduced the cell apoptosis compared to mimics NC (20.22 ± 4.51% vs. 31.22 ± 3.35%, \( p < 0.01 \)), whereas the inhibitors increased that compared to inhibitors-NC (45.44 ± 5.28% vs. 35.02 ± 6.22%, \( p < 0.05 \)) (Fig. 7D, E), confirming the protective effects of miR-146a-5p on H9C2 cells under H/SD conditions.
Fig. 5 (See legend on previous page.)
Based on the prediction results of TargetScan, *Irak1* ranked highest among the predicted targets of *miR-146a-5p*, with two predicted target sites for *miR-146a-5p* in the 3′-untranslated region (3′-UTR) of the transcript of *Irak1* (Additional file 1: Table S6). To further confirm whether *miR-146a-5p* directly binds to the 3′-UTR of *Irak1*, we cloned the wild-type and mutant 3′-UTR of *Irak1* downstream of a firefly luciferase cassette in a luciferase reporter vector (Additional file 1: Fig. S3). As expected, *miR-146a-5p* mimics exclusively inhibited the luciferase activity of wild-type, suggesting that *miR-146a-5p* bound the *Irak1* mRNA 3′-UTR and thereby inhibited *Irak1* (Fig. 7F). Under H/SD conditions, both the mRNA and protein levels of IRAK1 in H9C2 cells were obviously increased (Fig. 7G-I). After transfection with *miR-146a-5p* mimics, inhibitors or the corresponding NCs, qPCR analysis indicated that *miR-146a-5p* mimics resulted in a significant decrease in *Irak1* mRNA levels (*p* < 0.01), while *miR-146a-5p* inhibitors resulted in a notably higher level (*p* < 0.05) (Fig. 7J). Western blot analysis further demonstrated that transfection with *miR-146a-5p* mimics resulted in a significant increase in IRAK1 protein levels (*p* < 0.01), while *miR-146a-5p* inhibitors indicated the opposite result (*p* < 0.05) (Fig. 7K, L). More significantly decreased level of IRAK1 was detected in MSCsTXL-exo than MSCs-exo group both in vivo and in vitro (both *p* < 0.05) (Fig. 7M–P). We further detected the expression levels of NF-κB p65 and found that *miR-146a-5p* mimics suppressed NF-κB p65 subunit nuclear translocation (mean ± SD = 0.001 vs. mimics NC), whereas transfection with *miR-146a-5p* inhibitors indicated the opposite result (mean ± SD = 0.005 vs. inhibitors-NC) (Fig. 7Q, R). These results suggested the vital role of *miR-146a-5p* in inhibiting IRAK1 and NF-κB p65 subunit nuclear translocation in hypoxia-induced injury.

To further validate whether IRAK1 could regulate the nuclear translocation of NF-κB p65, we knocked down *Irak1* in H9C2 cells with siRNA. The knockdown efficiency of *Irak1* siRNA was validated by qPCR and western blotting (Additional file 1: Fig. S4). We found that knockdown of *Irak1* significantly reduced H9C2 cell apoptosis under H/SD conditions (*p* < 0.05 vs. siRNA-NC) (Fig. 7S, T) and further inhibited the nuclear translocation of NF-κB p65 in H9C2 cells in response to H/SD injury (*p* < 0.05 vs. siRNA-NC) (Fig. 7U, V).

Taken together, these results indicated that *miR-146a-5p* could protect H9C2 cells against hypoxic injury by inhibiting the IRAK1/NF-κB p65 pathway.

**Discussion**

Post-AMI, massive cardiomyocyte loss and an intense inflammatory response result in deteriorated cardiac function and worse clinical outcomes [3–5]. Preventing the loss of cardiomyocytes early and suppressing inflammation in a timely manner are effective strategies in AMI treatment [43–45]. MSCs therapies have been recognized as promising for cardiac repair of AMI due to anti-apoptotic and anti-inflammatory effects [29, 46, 47], though the clinical efficacy of BMs, including MSCs, was quite weak for AMI patients in clinical trials [8–11]. Therefore, numerous strategies have been developed to improve MSCs-based cardiac repair, including harsh microenvironment improvement in the infarcted region to promote the survival of implanted MSCs [19–21] as well as MSCs modifications [12–17, 26–28]. Although genetically modified approaches are the most effective strategy for increasing the therapeutic efficacy of MSCs, these approaches are currently infeasible in clinical practice and even suffer from difficulty achieving clinical translation. Instead, MSCs pretreated with drugs seem to be a promising solution to enhance cardiac repair effects with the potential for clinical translation in AMI treatment [26–28, 37].

TXL capsules, a Chinese medicine for patients with coronary artery disease [48–50], were reported in our previous studies to have cardioprotective effects through anti-apoptotic and anti-inflammatory mechanisms [24, 51–53], and to directly protect MSCs from apoptosis under H/SD conditions [23]. Therefore, we explored the effects of MSCsTXL in enhancing cardiac repair in AMI and the main findings were as follows: (1) MSCsTXL indeed facilitated cardiac repair with superior anti-apoptotic and anti-inflammatory effects at an early stage of...
AMI and achieved better cardiac function recovery via exosome secretion; (2) miR-146a-5p was enriched in MSCsTXL-exo (tenfold higher than that in MSCs-exo), which played a critical role in the marked cardioprotective effects of MSCsTXL-exo; (3) The transfer of exosomal miR-146a-5p into cardiomyocytes where IRAK1/NF-κB...
miR-146a-5p protected H9C2 cells from hypoxia injury by downregulating IRAK1 and inhibiting the nuclear translocation of the NF-κB p65 subunit. A. The miR-146a-5p level of H9C2 cells was significantly reduced under H/SD conditions (n = 5). miR-146a-5p mimics significantly increased (B) or miR-146a-5p inhibitors significantly decreased (C) miR-146a-5p levels in H9C2 cells (n = 3). Representative images of the flow cytometry assay (D) and quantification (E) of apoptotic H9C2 cells transfected with miR-146a-5p mimics, inhibitors or the corresponding negative control (n = 5). F. Luciferase activity assay of miR-146a-5p mimics-treated HEK293T cells, which overexpressed either IRAK1-wild-type or IRAK1-mutant. Under H/SD conditions, both the mRNA (G, n = 4) and protein levels of IRAK1 (H-I, n = 4) were obviously reduced. J. The mRNA level of Irak1 in H9C2 cells transfected with miR-146a-5p mimics, inhibitors or NC (n = 4). Representative western blotting images (K) and quantification (L) of the relative level of IRAK1 (n = 4). Western blotting images (M or O) and quantification (N or P) of the relative level of NF-κB p65 in MSCs-TXL treatment in vivo or in vitro. Representative images (Q) and quantification (R) of the relative level of NF-κB p65 (n = 3). Representative images of flow cytometry (S) and quantification (T) of apoptotic H9C2 cells transfected with IRAK1 siRNA or its NC (n = 4). Representative western blotting images (U) and quantification (V) of nuclear NF-κB p65 levels in H9C2 cells transfected with IRAK1 siRNA or its NC (n = 3). All data are presented as the mean ± SD. Statistical analysis was performed with one-way ANOVA or student's t test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
p65 signaling pathway was inhibited at least partially mediated the above superior protective effects of MSCsTXL.

Inflammation in response to myocardium necrosis after AMI is the physiological process of cardiac repair [4, 5]; however, prolonged or excessive inflammation might lead to catastrophic consequences, such as further loss of cardiomyocytes and then impairment of systolic function, ventricular remodeling, matrix degradation or even cardiac rupture [44]. Thus, proper and timely inhibition of inflammation is the target of treatment for AMI [45, 54]. MSCs are promising for cardiac repair in the treatment of AMI due to their anti-inflammatory, anti-apoptotic, and safe biological product in clinical use, MSCsTXL-exo [30–32]. Modified MSCs, such as hypoxia-mediated by paracrine actions [29] and the transfer of MSCsTXL-exo also had better cardiac repair effects than MSCs-exo in preventing H9C2 cells from undergoing apoptosis and inflammation accompanied by better cardiac function recovery and smaller infarct size. In addition, the cardiac repair effects of MSCsTXL were also dependent on secreted exosomes.

The cardioprotective effects of MSCs are primarily mediated by paracrine actions [29] and the transfer of exosome/EVs packed with bioactive proteins, RNAs and lipids [30, 31]. Modified MSCs, such as hypoxia- and GATA-4-modified MSCs [56], facilitated therapeutic effects mainly via secreted exosomes. Therefore, we confirmed in vitro that MSCsTXL-exo were superior to MSCs-exo in preventing H9C2 cells from undergoing apoptosis under H/SD conditions and further found that MSCsTXL-exo also had better cardiac repair effects than MSCs-exo in reducing cardiomyocyte apoptosis and inflammation accompanied by better cardiac function recovery and smaller infarct size in vivo. Exosomes, in contrast to their parent cells, possess the distinct features of immune tolerability and product stability while retaining bioactivity, thus having the advantages of clinically repeatable administration and presenting a safer and more feasible option for clinical use [57]. Even xenogeneic exosomes were reported to recapitulate the entire benefit profile of auto- or allogeneic cardiosphere-derived cells (CDCs) without apparent side-effects in a preclinical study [58]. Considering that exosomes might be a promising cell-free and safe biological product in clinical use, MSCsTXL-exo would have great potential for clinical translation in AMI treatment.

Bioactive miRNAs packed in exosomes play key roles in the treatment of myocardial infarction or injury [36], by participating in inflammation modulation, cardiac repair and cardiac fibrosis [31, 59]. Thus, we performed exosomal miRNA sequencing and found the enriched miR-146a-5p to be the candidate effector of the outstanding cardioprotective effects of MSCsTXL-exo. Increased level of miR-146a-5p has been confirmed to decrease ischemia-related injury in different organs including the myocardium, cerebrum, intestine and kidney [60–63]. As a highly enriched miRNA in both CDC-exosomes and cardiac progenitor cell-exosomes, miR-146a is the critical agent mediating the cardioprotective effects of stem cell therapy [38, 40, 64]. The transfer of exosomal miR-146a has also been reported to inhibit apoptosis, promote the proliferation of cardiomyocytes and augment angiogenesis [38, 65]. We further found that miR-146a-5p was the highly enriched miRNA in MSCsTXL-exo (> tenfold higher than in MSCs-exo) and that MSCsTXL-exo yielded stronger than MSCs-exo in mediating cardioprotective effects in anti-apoptosis, anti-inflammation, cardiac function improvement and infarct size reduction. Since serum miR-146a-5p levels were significantly lower than those in healthy controls in the first 24-h-serum samples from ST-elevated MI (STEMI) patients [66], the early administration of MSCsTXL-exo might be a promising strategy with clinical implications in STEMI patients.

After exploring the downstream mechanism of exosomal miR-146a-5p, we confirmed that it could down-regulate the level of IRAK1. IRAK1 is a vital adaptor molecule in the Toll-like receptor (TLR) and IL-1 receptor (IL-1R) signaling cascades mediating the activation of NF-κB pathways [67–69]. miR-146a-5p-mediated downregulation of IRAK1 has been reported to suppress inflammatory responses in acute lung injury [70] and to decrease myocardial or renal ischemia/reperfusion injury [38, 60, 63]. Our data confirmed the vital role of IRAK1 downregulation in reducing cardiomyocyte apoptosis by IRAK1 knockdown. Previous studies have revealed that IRAK1 deletion disrupts the activation of NF-κB [71], which is associated with the inflammatory response and cell survival [72]. Our in vivo data found that downregulation of IRAK1 inhibited the nuclear translocation of NF-κB p65 and then protected cardiomyocytes against hypoxic injury. Therefore, our results demonstrated that exosomal miR-146a-5p upregulation by MSCsTXL facilitated cardiac repair effects by inhibiting the IRAK1/NF-κB p65 signaling pathway.

Nevertheless, there are still several limitations in this study that should be noted. First, although intramyocardial injection is a highly effective route of MSCs or MSC-derived-exosomes delivery to the target area, other delivery routes, including intracoronary, especially intravenous injection, which are much more feasible in clinical use, deserve further study. Second, exosomes enriched in miR-146a-5p can also be taken up by other cell types in the heart which may exert other unknown effects. Third, other RNAs or proteins may exert synonymous
or synergistic effects with miR-146a-5p which also remains to be studied. Finally, further preclinical studies including direct transplantation of MSCs-TXL-inhibitors and MSCs-TXL-inhibitors-NC to AMI models are needed to validate its efficacy and safety for clinical translation.

**Conclusions**

Based on the anti-apoptotic and anti-inflammatory effects of the Chinese medicine TXL, our study highlighted the superior effects of MSCs-TXL in facilitating cardiac repair in AMI treatment and found that MSCs-TXL markedly enhanced cardiac repair via the transfer of exosomal miR-146a-5p to cardiomyocytes, which mediated cardioprotective effects by inhibiting the IRAK1/NF-κB signaling pathway. The study found a feasible strategy to enhance the therapeutic efficacy of MSCs and provided novel insights into the underlying mechanisms, which has clinical translational potential for AMI treatment.

**Abbreviations**

BMCs: Bone marrow cells; MSCs: Mesenchymal stem cells; SD: Sprague–Dawley; TXL: Tongxinluo; AMI: Acute myocardial infarction; IRAK1: Interleukin-1 receptor-associated kinase; NF-κB: Nuclear factor-κB; miRNA: MicroRNA; H/ SD: Hypoxia and serum deprivation; PBS: Phosphate-buffered saline; LAD: Left anterior descending coronary artery; TEM: Transmission electron microscope; NTA: Nanoparticle tracking analysis; LVFS: Left ventricular fractional shortening; LVEDV: Left ventricular end-diastolic volume; LVEF: Left ventricular ejection fraction; CDCs: Cardiosphere-derived cells.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13287-022-02969-y.

**Acknowledgements**

We thank Yan Song, Kejia Zhong, Jian Meng and Shuo Gao in the State Key Laboratory of Cardiovascular Disease for their technical assistance.

**Author contributions**

YX, RT, JX and GC have substantial contributions to the conception and design of the study. YX, RT, WJ, ZG, LZ, YN, PH, JX, XL, MH and JX contributed to animal model construction, data collection and analysis; YX, RT and JX drafted the manuscript; YX, CW, CJ, XL, HQ and YY contributed to the critical revision of the manuscript. All authors read and approved the final manuscript.

**Funding**

This project was supported by grants from the National Key Research and Development Program of China (No. 2017YFC1700503), CAMS Innovation Fund for Medical Sciences (CIFMS) (2016-12M-1-009), and the National Natural Science Foundation of China (Nos. 81573957, 81774292, 81874461, 82100313 and 82070307).

**Availability of data and materials**

The datasets generated and analyzed during the current study are available in Gene Expression Omnibus (GSE184067), https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE184067.

**Declarations**

**Ethics approval and consent to participate**
Not applicable.

**Consent for publication**
Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

Received: 12 October 2021 Accepted: 21 February 2022
Published online: 07 July 2022

**References**

1. Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abers SF, Abuyu G, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25.
2. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e199–596.
3. Suleiman M, Khatib R, Agmon Y, Mahamid R, Boulos M, Kapelliovich M, et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol. 2006;47(5):962–8.
4. Prabhuv SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ Res. 2016;119(1):91–112.
5. Ong SB, Hernandez-Resendiz S, Crespo-Avilan GE, Muharmetshina RT, Kwek XY, Cabrera-Fuentes HA, et al. Inflammation following acute myocardial infarction: multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacol Ther. 2018;186:75–87.
6. Afzal MR, Samanta A, Shah ZJ, Jeevanantham V, Abdel-Latif A, Zab-Surma EK, et al. Adult bone marrow cell therapy for ischemic heart disease-evidence and insights from randomized controlled trials. Circ Res. 2015;117(6):558–75.
7. Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation. 2003;108(7):863–8.
8. Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med. 2006;355(12):1199–209.
9. Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet W, et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet. 2006;367(9505):113–21.
10. Hashemi SM, Ghods S, Kolodgie FD, Parcham-Azad K, Keane M, Hamamdzic D, et al. A placebo controlled, dose-ranging, safety study of autologous mesenchymal stem cells injected by endomyocardial delivery after an acute myocardial infarction. Eur Heart J. 2008;29(2):251–9.
11. Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, et al. Autologous bone marrow-derived stem-cell transfer in patients with acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011;306(19):2110–9.
12. Hahn JY, Cho HJ, Kang HJ, Kim TS, Kim MH, Chung JH, et al. Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytotoxic effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J Am Coll Cardiol. 2008;51(9):933–43.
13. Hu X, Xu Y, Zhong Z, Wu Y, Zhao J, Wang Y, et al. A large-scale investigation of hypoxia-preconditioned allogeneic mesenchymal stem cells for...
myocardial repair in nonhuman primates: paracrine activity without remuscularization. Circ Res. 2010;118(6):970–83.

14. Deuse T, Peter C, Fedak PW, Doyle T, Reichenspurner H, Zimmermann WH, et al. Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation. 2009;120(11 Suppl):S247–54.

15. Huang J, Zhang Z, Guo J, Ni A, Deb A, Zhang L, et al. Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circ. 2010;116(11):1753–62.

16. Wei HJ, Chen CH, Lee WY, Chiu J, Hwang SM, Lin WW, et al. Bioengineered cardiac patch constructed from multilayered mesenchymal stem cells for myocardial repair. Biomaterials. 2008;29(26):3547–56.

17. You Y, Kobayashi K, Colak B, Luo P, Cozens E, Fields L, et al. Engineered cell-degradable poly(2-alkyl-2-oxazoline) hydrogel for epicardial placement of mesenchymal stem cells for myocardial repair. Biomaterials. 2021;269:120356.

18. Qian HY, Yang YJ, Huang J, Gao RL, Dou KF, Yang GS, et al. Effects of Tongxinluo-facilitated cellular cardiomyoplasty with autologous bone marrow-mesenchymal stem cells on postinfarct swine hearts. Chin Med J (Engl). 2007;120(16):1416–25.

19. Yang YJ, Qian HY, Huang J, Geng YJ, Gao RL, Dou KF, et al. Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. Eur J Heart Fail. 2008;10(12):1578–90.

20. Yang YJ, Qian HY, Huang J, Li J, Gao RL, Dou KF, et al. Combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells increases benefits in infarcted swine hearts. Arterioscler Thromb Vasc Biol. 2009;29(12):2076–82.

21. Yang YJ, Qian HY, Song L, Geng YJ, Gao RL, Li N, et al. Strengthening effects of bone marrow mononuclear cells with intensive atorvastatin in acute myocardial infarction. Open Heart. 2020;7(1):e001139.

22. Dong Q, Yang Y, Song L, Qian H, Xu Z. Atorvastatin prevents mesenchymal stem cells from hypoxia and serum-free injury through activating AMP-activated protein kinase. Int J Cardiol. 2011;153(3):311–6.

23. Li N, Yang YJ, Cui HH, Zhang Q, Jin C, Qian HY, et al. Tonicinlow decreases apoptosis of mesenchymal stem cells concentration-dependently under hypoxia and serum deprivation conditions through the AMPK/eNOS pathway. J Cardiovasc Pharmacol. 2014;63(3):265–73.

24. Li Q, Li N, Cui HH, Tian XQ, Jin C, Chen GH, et al. Tonicinlow exerts protective effects via anti-apoptotic and pro-autophagic mechanisms by activating AMPK pathway in infarcted rat hearts. Exp Physiol. 2017;102(6):422–35.

25. Li Q, Dong QT, Yang YJ, Tian XQ, Jin C, Hu FH, et al. AMPK-mediated cardioprotection of atorvastatin relates to the reduction of apoptosis and activation of autophagy in infarcted rat hearts. Am J Transl Res. 2016;8(10):4160–71.

26. Li N, Yang YJ, Qian HY, Li Q, Zhang Q, Li XD, et al. Intrafusal administration of atorvastatin-pretreated mesenchymal stem cells improves cardiac performance after acute myocardial infarction: role of CXCR4. Am J Transl Res. 2015;7(6):1058–70.

27. Tian XQ, Yang YJ, Li Q, Xu J, Huang PS, Xiong YY, et al. Combined therapy with atorvastatin and atorvastatin-pretreated mesenchymal stem cells enhances cardiac performance after acute myocardial infarction by activating SDF-1/CXCR4 axis. Am J Transl Res. 2019;11(7):4214–31.

28. Xu L, Xiong YY, Li Q, Hu MJ, Huang PS, Xu JY, et al. Optimization of timing and times for administration of atorvastatin-pretreated mesenchymal stem cells in a preclinical model of acute myocardial infarction. Stem Cells Transl Med. 2019;8(10):1068–83.

29. Golpanian S, Wolf A, Hatzigergos KE, Hare JM. Rebuilding the damaged heart: mesenchymal stem cells, cell-based therapy, and engineered heart tissue. Physiol Rev. 2016;96(3):1127–68.

30. Jansen F, Nickenig G, Werner N. Extracellular vesicles in cardiovascular disease: potential applications in diagnosis, prognosis, and epidemiology. Circ Res. 2017;120(10):1649–57.

31. Sahoo S, Losordo DW. Exosomes and cardiac repair after myocardial infarction. Circ Res. 2014;114(2):333–44.

32. Barile L, Moccetti T, Marban E, Vassalli G. Roles of exosomes in cardioprotection. Eur Heart J. 2017;38(18):1372–9.

33. Tkach M, Théry C. Communication by extracellular vesicles: where we are and where we need to go. Cell. 2016;164(6):1226–32.
56. He JG, Li HR, Han JX, Li BB, Yan D, Li HY, et al. GATA-4-expressing mouse bone marrow mesenchymal stem cells improve cardiac function after myocardial infarction via secreted exosomes. Sci Rep. 2018;8(1):9047.

57. Marbán E. The secret life of exosomes: what bees can teach us about next-generation therapeutics. J Am Coll Cardiol. 2018;71(2):195–200.

58. Gallet R, Dawkins J, Valle J, Simons L, de Couto G, Middleton R, et al. Exosomes secreted by cardioprotective cells reduce scar size, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction. Eur Heart J. 2017;38(3):201–11.

59. de Abreu RC, Fernandes H, da Costa Martins PA, Sahoo S, Emanuelli C, Ferreira L. Native and bioengineered extracellular vesicles for cardiovascular therapeutics. Nat Rev Cardiol. 2020;17(11):685–97.

60. Wang X, Ha T, Liu L, Zou J, Zhang X, Kalbfleisch J, et al. Increased expression of microRNA-146a decreases myocardial ischaemia-reperfusion injury. Cardiovasc Res. 2013;97(3):432–42.

61. Chu B, Zhou Y, Zhai H, Li L, Sun L, Li Y. The role of microRNA-146a in regulating the expression of IRAK1 in atherosclerosis. PLoS One. 2016;11(6):1–8.

62. Chassin C, Hempel C, Stockinger S, Dupont A, Kübler JF, Wedemeyer J, et al. MicroRNA-146a-mediated downregulation of IRAK1 protects mouse and human small intestine against ischemia/reperfusion injury. EMBO Mol Med. 2012;4(12):1508–19.

63. Li X, Xiao J, Su X, Li W, Bi Z, Wang J, et al. Human urine-derived stem cells protect against renal ischemia/reperfusion injury in a rat model via exosomal miR-146a-5p which targets IRAK1. Theranostics. 2020;10(21):9561–78.

64. Milano G, Biemmi V, Lazzarin E, Balm C, Ciullo A, Bolis S, et al. Intravenous administration of cardiac progenitor cell-derived exosomes protects against doxorubicin/TNFα-induced cardiac toxicity. Cardiovasc Res. 2020;116(2):383–92.

65. Cheng HS, Sivachandran N, Lau A, Boudreau E, Zhao JL, Baltimore D, et al. MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways. EMBO Mol Med. 2013;5(7):1017–34.

66. Bukauskas T, Mickus R, Cereskevicius D, Macas A. Value of Serum miR-23a, miR-30d, and miR-146a Biomarkers in ST-Elevation Myocardial Infarction. Med Sci Monit. 2019;25:5925–32.

67. Gottipati S, Rao NL, Fung-Leung WP. IRAK1: a critical signaling mediator of innate immunity. Cell Signal. 2008;20(2):269–76.

68. Ghosh S, Dass JFP. Study of pathway cross-talk interactions with NF-κB leading to its activation via ubiquitination or phosphorylation: a brief review. Gene. 2016;584(1):97–109.

69. Su LC, Xu WD, Huang AF. IRAK family in inflammatory autoimmune diseases. Autoimmun Rev. 2020;19(3):102461.

70. Zeng Z, Gong H, Li Y, Jie K, Ding C, Shao Q, et al. Uregulation of miR-146a contributes to the suppression of inflammatory responses in LPS-induced acute lung injury. Exp Lung Res. 2013;39(7):275–82.

71. Thomas JA, Haudek SB, Koroglu T, Tsien MF, Bryant DD, White DJ, et al. IRAK1 deletion disrupts cardiac Toll/IL-1 signaling and protects against contractile dysfunction. Am J Physiol Heart Circ Physiol. 2003;285(2):H597-606.

72. Ockinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-κB signaling pathways. Nat Immunol. 2011;12(8):695–708.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.